Novavax Stock Forecast, Price & News

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novavax in the last year. There are currently 1 sell rating, 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Novavax stock.
View analyst ratings for Novavax or view top-rated stocks.

Wall Street analysts have given Novavax a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Novavax wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Novavax is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for Novavax.

Novavax will be holding an earnings conference call on Thursday, August 5th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link or dial in at 412-317-0088 with passcode "10158313".

Novavax, Inc. (NASDAQ:NVAX) announced its quarterly earnings results on Monday, May, 10th. The biopharmaceutical company reported ($3.05) earnings per share for the quarter, missing the Zacks' consensus estimate of ($2.65) by $0.40. The biopharmaceutical company had revenue of $447 million for the quarter, compared to analysts' expectations of $233.90 million. Novavax had a negative trailing twelve-month return on equity of 125.71% and a negative net margin of 66.90%. Novavax's revenue for the quarter was up 13124.9% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.58) EPS.
View Novavax's earnings history.

Novavax's stock was trading at $10.51 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, NVAX stock has increased by 1,606.3% and is now trading at $179.33.
View which stocks have been most impacted by COVID-19.

Novavax shares reverse split on Friday, May 10th 2019. The 1-20 reverse split was announced on Wednesday, May 8th 2019. The number of shares owned by shareholders was adjusted after the market closes on Thursday, May 9th 2019. An investor that had 100 shares of Novavax stock prior to the reverse split would have 5 shares after the split.

6 brokers have issued 12 month price objectives for Novavax's stock. Their forecasts range from $105.00 to $294.00. On average, they anticipate Novavax's stock price to reach $225.50 in the next twelve months. This suggests a possible upside of 25.7% from the stock's current price.
View analysts' price targets for Novavax or view top-rated stocks among Wall Street analysts.

46 employees have rated Novavax CEO Stanley C. Erck on Glassdoor.com. Stanley C. Erck has an approval rating of 71% among Novavax's employees.

Some companies that are related to Novavax include Amgen (AMGN), Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Alexion Pharmaceuticals (ALXN), Seagen (SGEN), Alnylam Pharmaceuticals (ALNY), Exact Sciences (EXAS), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Repligen (RGEN), Neurocrine Biosciences (NBIX), United Therapeutics (UTHR) and Halozyme Therapeutics (HALO).
View all of NVAX's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Novavax investors own include Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Moderna (MRNA), NVIDIA (NVDA), Tesla (TSLA), Palo Alto Networks (PANW), Advanced Micro Devices (AMD), Egalet (EGLT), Exact Sciences (EXAS) and Pfizer (PFE).

Novavax trades on the NASDAQ under the ticker symbol "NVAX."

Novavax's stock is owned by many different retail and institutional investors. Top institutional shareholders include Oregon Public Employees Retirement Fund (0.03%), IFM Investors Pty Ltd (0.01%), Stratos Wealth Partners LTD. (0.00%), Gradient Investments LLC (0.00%), Compagnie Lombard Odier SCmA (0.00%) and Tradewinds Capital Management LLC (0.00%). Company insiders that own Novavax stock include Gary C Evans, Gregory M Glenn, James F Young, John A Herrmann III, John Trizzino, Michael A Mcmanus Jr, Rachel K King and Stanley C Erck.
View institutional ownership trends for Novavax.

NVAX stock was sold by a variety of institutional investors in the last quarter, including Compagnie Lombard Odier SCmA. Company insiders that have sold Novavax company stock in the last year include Gary C Evans, Gregory M Glenn, James F Young, John A Herrmann III, John Trizzino, Michael A Mcmanus Jr, and Stanley C Erck.
View insider buying and selling activity for Novavax or view top insider-selling stocks.

NVAX stock was purchased by a variety of institutional investors in the last quarter, including Oregon Public Employees Retirement Fund, IFM Investors Pty Ltd, Stratos Wealth Partners LTD., Tradewinds Capital Management LLC, Gradient Investments LLC, and Red Door Wealth Management LLC. Company insiders that have bought Novavax stock in the last two years include Gregory M Glenn, James F Young, and Rachel K King.
View insider buying and selling activity for Novavax or or view top insider-buying stocks.

Shares of NVAX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of NVAX stock can currently be purchased for approximately $179.33.

Novavax has a market capitalization of $13.29 billion and generates $475.60 million in revenue each year. The biopharmaceutical company earns $-418,260,000.00 in net income (profit) each year or ($7.27) on an earnings per share basis.

Novavax employs 792 workers across the globe.

Novavax was founded in 1987.

The official website for Novavax is www.novavax.com.

Novavax is headquartered at 21 FIRSTFIELD ROAD, GAITHERSBURG MD, 20878.

Novavax's mailing address is 21 FIRSTFIELD ROAD, GAITHERSBURG MD, 20878. The biopharmaceutical company can be reached via phone at 240-268-2000 or via email at [email protected]